Literature DB >> 11286660

Will New Human Papillomavirus Diagnostics Improve Cervical Cancer Control Efforts?

Shalini L. Kulasingam1, Laura A. Koutsky.   

Abstract

With the causal link between specific types of human papillomavirus (HPV) and cervical cancer firmly established, efforts have turned to assessing the relative merits of offering HPV testing in screening, triage, and posttreatment management. Many unanswered questions remain, but a growing body of evidence supports a role for HPV testing in cervical cancer prevention programs. Already, clinical centers that serve thousands of women in Europe and the United States have incorporated HPV DNA tests in triage algorithms.

Entities:  

Year:  2001        PMID: 11286660     DOI: 10.1007/s11908-996-0054-0

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  56 in total

1.  Human papillomavirus testing for primary cervical cancer screening.

Authors:  J Cuzick
Journal:  JAMA       Date:  2000-01-05       Impact factor: 56.272

2.  ACOG committee opinion. Recommendations on frequency of Pap test screening. Number 152--March 1995. Committee on Gynecologic Practice. American College of Obstetricians and Gynecologists.

Authors: 
Journal:  Int J Gynaecol Obstet       Date:  1995-05       Impact factor: 3.561

3.  HPV-based cervical cancer screening in a population at high risk for HIV infection.

Authors:  S D Womack; Z M Chirenje; L Gaffikin; P D Blumenthal; J A McGrath; T Chipato; S Ngwalle; M Munjoma; K V Shah
Journal:  Int J Cancer       Date:  2000-01-15       Impact factor: 7.396

4.  Human papillomavirus detection by the hybrid capture II assay: a reliable test to select women with normal cervical smears at risk for developing cervical lesions.

Authors:  C Clavel; M Masure; M Levert; I Putaud; C Mangeonjean; M Lorenzato; P Nazeyrollas; R Gabriel; C Quereux; P Birembaut
Journal:  Diagn Mol Pathol       Date:  2000-09

5.  Human papillomavirus infection in women infected with the human immunodeficiency virus.

Authors:  X W Sun; L Kuhn; T V Ellerbrock; M A Chiasson; T J Bush; T C Wright
Journal:  N Engl J Med       Date:  1997-11-06       Impact factor: 91.245

6.  Human papillomavirus (HPV) DNA copy number is dependent on grade of cervical disease and HPV type.

Authors:  D C Swan; R A Tucker; G Tortolero-Luna; M F Mitchell; L Wideroff; E R Unger; R A Nisenbaum; W C Reeves; J P Icenogle
Journal:  J Clin Microbiol       Date:  1999-04       Impact factor: 5.948

7.  Human papillomavirus testing as triage for atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesions: sensitivity, specificity, and cost-effectiveness.

Authors:  R H Kaufman; E Adam; J Icenogle; W C Reeves
Journal:  Am J Obstet Gynecol       Date:  1997-10       Impact factor: 8.661

8.  False-negative results in cervical cytologic studies.

Authors:  J D Gay; L D Donaldson; J R Goellner
Journal:  Acta Cytol       Date:  1985 Nov-Dec       Impact factor: 2.319

9.  A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection.

Authors:  L A Koutsky; K K Holmes; C W Critchlow; C E Stevens; J Paavonen; A M Beckmann; T A DeRouen; D A Galloway; D Vernon; N B Kiviat
Journal:  N Engl J Med       Date:  1992-10-29       Impact factor: 91.245

10.  Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia.

Authors:  G Y Ho; R D Burk; S Klein; A S Kadish; C J Chang; P Palan; J Basu; R Tachezy; R Lewis; S Romney
Journal:  J Natl Cancer Inst       Date:  1995-09-20       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.